Results 31 to 40 of about 799 (135)

Mce3R Stress-Resistance Pathway Is Vulnerable to Small-Molecule Targeting That Improves Tuberculosis Drug Activities. [PDF]

ACS Infect Dis, 2019
Yang X, Yuan T, Ma R, Chacko KI, Smith M, Deikus G, Sebra R, Kasarskis A, van Bakel H, Franzblau SG, Sampson NS.   +10 more
europepmc   +1 more source

Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives. [PDF]

Oxid Med Cell Longev, 2022
Semwal P, Painuli S, Abu-Izneid T, Rauf A, Sharma A, Daştan SD, Kumar M, Alshehri MM, Taheri Y, Das R, Mitra S, Emran TB, Sharifi-Rad J, Calina D, Cho WC.   +14 more
europepmc   +1 more source

Recurrent Anti-AMPA Receptor Limbic Encephalitis: A Case Report and Literature Review. [PDF]

Front Neurol, 2021
Fang Y, Pan D, Huang H.
europepmc   +1 more source

Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives. [PDF]

J Enzyme Inhib Med Chem
Cerra B, Gioiello A.
europepmc   +1 more source

Azasteroide. III

YAKUGAKU ZASSHI, 1958
openaire   +2 more sources

Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia. [PDF]

Int J Urol
Inamura S, Fukiage Y, Kobayashi H, Tsutsumiuchi M, Seki M, Taga M, Fukushima M, Kobayashi M, Yokoyama O, Terada N.   +9 more
europepmc   +1 more source

Azasteroid. IV

YAKUGAKU ZASSHI, 1958
openaire   +2 more sources

On the Azasteroids

Journal of Synthetic Organic Chemistry, Japan, 1972
openaire   +2 more sources

Anticancer Activities of Natural and Synthetic Steroids: A Review. [PDF]

ACS Omega
Mendoza Lara DF, Hernández-Caballero ME, Terán JL, Ramírez JS, Carrasco-Carballo A.   +4 more
europepmc   +1 more source

Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. [PDF]

Cancer
Zheng R, Daniels JP, Moreira DM, Eslamimehr S, Freedland AR, Guerrios-Rivera L, Fowke JH, Freedland SJ.   +7 more
europepmc   +1 more source